Acquiring Company
Helus Pharma
Acquired Company
the CYB004-E Study
TorontoOtherManufacturingBiotechnologyHealth CarePharmaceuticalOtherConsumer GoodsScience And EngineeringGovernment And MilitaryDescription
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”). This DMT study, which is the largest to date, is expected to accelerate the clinical development path of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months. The Company previously announced details of the Acquisition on June 7, 2022.
Other recent acquisitions in Pharmaceutical and Consumer Goods
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- U.S. Alliance Pharma Acquires U.K.-Based Lgc’S Drug Development Solutions (Dds) Business (July 13, 2022)
- Cybin Acquires Dmt Clinical Study From Entheon Biomedical (June 7, 2022)
- Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio (August 17, 2022)
- Catalent To Acquire Metrics Contract Services For $475 Million To Expand High-Potent Capabilities And Oral Development And Manufacturing Capacity, $475M (August 9, 2022)
- Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company (June 3, 2022)
Who to call at Helus Pharma, and when
When Helus Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Helus Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Helus Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Helus Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Helus Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired the CYB004-E Study?
the CYB004-E Study was acquired by Helus Pharma, based in Toronto. The deal was reported on July 11, 2022. Helus Pharma is a mental health-focused biopharmaceutical company developing small-molecule Novel Serotonergic Agonists (NSAs) to improve treatment options. Helus Pharma is publicly traded (HELP) and operates in Other.
When did Helus Pharma acquire the CYB004-E Study?
Helus Pharma's acquisition of the CYB004-E Study was reported on July 11, 2022. Cybin Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does the CYB004-E Study do?
The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of a target-controlled intravenous infusion of DMT in healthy smokers. It is privately held, operating in Other.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.